Sanofi Restructures $11.2 Billion Vaccine Business Amid Strategic Realignment

On April 18, 2024, Sanofi disclosed to the well-known foreign media Endpoints News that it is restructuring its vaccine commercial operations in the United States and implementing layoffs, with the specific number of layoffs unknown. Sanofi stated that this move aims to implement a "streamlined strategic sales structure" to better support its customers and patients, but did not disclose details such as the number of layoffs and the timeline. According to publicly reported news, this marks Sanofi's fourth announced layoff in 2024.

Previously, Sanofi announced its 2023 financial results, with revenue reaching 43.07 billion euros, a year-on-year increase of 5.3%. Of this, pharmaceutical business revenue was 37.89 billion euros, vaccine business revenue was 7.474 billion euros (approximately 59.2 billion RMB), and consumer healthcare business revenue was 5.180 billion euros, all showing growth trends.

This move can be regarded as part of Sanofi's "Play to Win" strategy.

Paul Hudson (hereinafter referred to as Paul), the current CEO of Sanofi, proposed and committed to implementing the five-year "Play to Win" plan shortly after joining the company in 2019. The plan shifts the focus to oncology and rare disease businesses while establishing three core global divisions: specialty medicines, general medicines, and vaccines, to concentrate resources on the development of innovative drugs and vaccines.

In 2020, Sanofi ranked 8th among global pharmaceutical companies with a net revenue of 36.041 billion euros. However, looking at Sanofi's products on sale in 2020, there were only two blockbuster innovative drugs, one of which, teriflunomide, is about to face generic drug competition. Therefore, dupilumab is the only drug that can still be relied upon.

Therefore, Sanofi’s main goal that year to implement the "Play to Win" strategy was to maximize the development and distribution of Dupilumab for treating Type 2 inflammatory diseases, expand its vaccine portfolio, and accelerate its potentially transformative therapy pipeline, aiming to achieve a 30% business operating income profit margin by 2022. Dupilumab did not disappoint, gradually becoming one of the world's leading drugs, with sales in the third quarter of 2023 nearing 11 billion euros.

However, over-reliance on and betting on a single product is never a good sign.

This might explain the weight of the vaccine business in the "Play to Win" strategy. Vaccines are a traditional business for Sanofi, inherited from the Mérieux Institute. Although not as large in scale as the pharmaceuticals business, vaccines have consistently been one of Sanofi’s fastest-growing and most advantageous sectors. In 2021, Sanofi reiterated its growth plan aligned with "Play to Win," pointing out that future sustained growth would primarily come from its four core franchises: meningitis, influenza, PPH3, and Boosters, along with the upcoming monoclonal antibody drug nirsevimab for infant respiratory syncytial virus (RSV).

This high-growth vaccine business has achieved mid-to-high single-digit sales growth since 2018, and it is expected that at least five new projects will enter the third phase by 2025.

On the other hand, Sanofi successfully launched six new drugs between 2021 and 2022, including Xenpozyme.^®、 Nexviazyme^®、Enjaymo^®、ALTUVIIIO^®、TZIELD^®And Beyfortus^®。

In the immunology and neuro-inflammation portfolio, there are seven promising pipelines in mid-to-late stage development, including itepekimab, tolebrutinib, amlitelimab, frexalimab, rilzabrutinib, SAR443765 (IL13/TSLP), and SAR441566 (oral TNFi). Each pipeline has a sales potential of up to 5 billion euros.

According to Sanofi's official website, since the implementation of the "Play to Win" strategy, Sanofi has continued its history of enriching its product pipeline through acquisitions, with approximately 30 business investments and pipeline deals in total.

Notably, in October 2023, when Sanofi released its Q3 financial report and announced a downgrade of its 2024 profit forecast, its CEO Paul Hudson reiterated the "Play to Win" strategy. Not only that, but to align with this strategy, Sanofi introduced pipeline prioritization adjustments and cost-cutting plans, while also signaling the potential spin-off of its consumer healthcare business. Additionally, Sanofi withdrew its 2025 profit target and unveiled a new cost-reduction initiative, stating that the company would no longer aim for a 32% BOI profit margin by 2025, while maintaining a focus on long-term profitability, aiming to save up to €2 billion from 2024 through the end of 2025.

Strategic Update: Following the release of Q3 earnings, Sanofi's stock plummeted 19.13%, wiping out $25.7 billion in market value overnight; marking the company’s largest single-day drop since its U.S. IPO in 2002, and becoming the biggest disaster for an MNC in nearly a decade.

What followed was not a turnaround in the situation, but a major blow to Sanofi's oncology strategy. At the end of 2023, the company’s ADC drug failed to outperform chemotherapy in a Phase 3 clinical trial for lung cancer treatment, leading Sanofi to decide to abandon its only ADC drug that was in the clinical stage.

Following Strategic Updates and ADC Product Setbacks, Sanofi's Stock Price Experienced a Significant Drop with Slow Recovery.

Since the beginning of 2024, perhaps in order to quickly adjust and break away from difficulties, Sanofi has successively abandoned oncology projects acquired from Denali, Kymab, and Amunix.

Among them, several major moves in April were the most eye-catching.

On April 9, Sanofi closed down the NK cell therapy company it acquired for nearly $400 million, parting ways with it. This move was quietly announced while updating the clinical trial information of SAR445419. SAR445419 is an allogeneic NK cell therapy developed by Sanofi for treating relapsed/refractory acute myeloid leukemia. According to the U.S. clinical trial database, the phase I study of SAR445419 was terminated due to Kiadis' withdrawal. Kiadis itself was also forced to "disappear" as a result of Sanofi's reprioritization.

On April 10, Sanofi divested another intangible asset impairment project, Amunix. The company announced the sale of a production facility located in San Francisco, which was acquired when Sanofi spent $1 billion to purchase Amunix Pharmaceuticals. It also revealed plans to cut 100 jobs in California.

Subsequently, IGM Biosciences, once a partner of Sanofi, also issued a statement indicating that the company had renegotiated its global exclusive cooperation agreement with Sanofi — abandoning the originally planned three targets in the oncology field and instead focusing on immunology/inflammation targets to create and develop lqM agonist antibodies. IGM will retain global rights to the proprietary technology related to the oncology targets specified in its collaboration with Sanofi. This means that IGM's nearly $3 billion in milestone payments have gone down the drain, and this cooperation, which began in March 2022, has been completely overhauled.

In the eyes of the industry, Sanofi's previous R&D and production efficiency were not high, and its R&D and M&A efforts were weak. There are reasons why Sanofi’s valuation is the lowest among multinational companies (MNCs). It remains to be seen whether the current management can reverse the situation. While adjusting its pipeline this time, Sanofi also reconsidered its development strategy—on one hand, advancing into the AI drug discovery track, and on the other hand, fully building up its immunology and vaccine businesses.

Paul Hudson stated that the company is facing a critical window period. Sanofi has almost no patent-expiring drugs, while many pharmaceutical companies are encountering a patent cliff. Additionally, Sanofi's vaccine business declined in 2023. Therefore, for Sanofi, it is essential to accelerate the development and launch of more innovative drugs to quickly capture the market from now until 2030. At present, all top pharmaceutical companies are streamlining their operations, and it is hoped that Sanofi’s major adjustments won’t come too late.